BioSpace News Archive

Policy

Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome

Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.

June 1, 2022
·
3 min read
BioMidwest

Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

Biodesix, Inc. announced Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9, 2022 at the Lowes Chicago Hotel in Chicago, IL.

June 1, 2022
·
4 min read
BioMidwest

Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19

Sonoma Pharmaceuticals, Inc. and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants maintained by the U.S. Environmental Protection Agency’s List N.

June 1, 2022
·
5 min read
Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes

Dexcom, Inc. announced that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island’s Diabetes Glucose Sensor Program.

June 1, 2022
·
5 min read
MolecuLight Added to the ISWCAP 2022 Consensus Guidelines for Optimising Prevention of Surgical Wound Complications

MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced that it has been added to the new 2022 Consensus Guidelines of the International Surgical Wound Complications Advisory Panel.

June 1, 2022
·
4 min read
Business

Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the first quarter ended March 31, 2022 and provided an update on clinical and corporate progress.

June 1, 2022
·
16 min read
Bioresorbable Activa IM-Nail™ shows convincing results in Post-Market Clinical Follow-up study for the treatment of children’s forearm fractures

Bioretec Ltd ( HELSINKI : BRETEC) Forearm fractures are a common injury in children and adolescents.

June 1, 2022
·
3 min read
Drug Development

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Sage Therapeutics, Inc. and Biogen Inc. announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression, met its primary and all key secondary endpoints.

June 1, 2022
·
16 min read
Biotech Beach

ChromaDex to Present at the LD Micro Invitational

ChromaDex Corp. announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational.

June 1, 2022
·
3 min read
Genetown

TCR² Therapeutics to Participate in Two Upcoming Conferences in June 2022

TCR2 Therapeutics Inc. announced that management will participate at two upcoming conferences in June in New York.

June 1, 2022
·
1 min read